[{"address1": "Rapsgatan 7E", "city": "Uppsala", "country": "Sweden", "phone": "46 1 87 80 88 00", "fax": "46 1 87 80 88 88", "website": "https://www.orexo.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.", "fullTimeEmployees": 112, "companyOfficers": [{"maxAge": 1, "name": "Mr. Nikolaj  Sorensen", "age": 51, "title": "President & CEO", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 5836000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Fredrik  Jarrsten", "age": 56, "title": "Executive VP & CFO", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Cecilia  Coupland", "age": 47, "title": "Senior VP & Head of Operations", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Lena  Wange", "title": "Investor Relations & Communications Director", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Ronn", "age": 47, "title": "Senior VP and Head of R&D", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Edward  Kim M.B.A., M.D.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert A. Deluca", "age": 62, "title": "President of Orexo US Inc", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jesper  Lind", "age": 63, "title": "Advisor", "yearBorn": 1960, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 3, "compensationRisk": 10, "shareHolderRightsRisk": 4, "overallRisk": 6, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "open": 1.5, "dayLow": 1.5, "dayHigh": 1.5, "regularMarketOpen": 1.5, "regularMarketDayLow": 1.5, "regularMarketDayHigh": 1.5, "beta": 0.567, "volume": 6945, "regularMarketVolume": 6945, "bid": 1.1, "ask": 2.06, "marketCap": 52373248, "fiftyTwoWeekLow": 1.04, "fiftyTwoWeekHigh": 1.95, "priceToSalesTrailing12Months": 0.08513207, "fiftyDayAverage": 1.5, "twoHundredDayAverage": 1.4884, "trailingAnnualDividendYield": "NaN", "currency": "USD", "enterpriseValue": 395056224, "profitMargins": -0.15702, "floatShares": 21143801, "sharesOutstanding": 34449600, "heldPercentInsiders": 0.19313, "heldPercentInstitutions": 0.37644002, "bookValue": 0.701, "priceToBook": 2.1398003, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -96600000, "trailingEps": -0.27, "enterpriseToRevenue": 0.642, "enterpriseToEbitda": 6.707, "exchange": "OQX", "quoteType": "EQUITY", "symbol": "ORXOF", "underlyingSymbol": "ORXOF", "shortName": "OREXO AB", "longName": "Orexo AB (publ)", "firstTradeDateEpochUtc": 1365687000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "c945e53d-d4e7-3f24-846a-dccaf05f0e30", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.5, "recommendationKey": "none", "totalCash": 139700000, "totalCashPerShare": 4.049, "ebitda": 58900000, "totalDebt": 483000000, "quickRatio": 1.507, "currentRatio": 1.769, "totalRevenue": 615200000, "debtToEquity": 1995.868, "revenuePerShare": 17.855, "returnOnAssets": 0.0050700004, "returnOnEquity": -1.30541, "freeCashflow": -2900000, "operatingCashflow": -49900000, "revenueGrowth": -0.023, "grossMargins": 0.88214993, "ebitdaMargins": 0.095740005, "operatingMargins": -0.121429995, "financialCurrency": "SEK", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]